stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) EPS (diluted)
AbCellera Biologics Inc.'s EPS (diluted) for fiscal 2025 was −$0.49, compared with −$0.55 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.54. Over the past ten years it has ranged from −$0.55 (fiscal 2024) to $0.50 (fiscal 2022); the current reading is higher than 38% of that period. AbCellera Biologics Inc. ranks 137th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.49 | — |
| FY2024 | −$0.55 | — |
| FY2023 | −$0.51 | — |
| FY2022 | $0.50 | 4.17% |
| FY2021 | $0.48 | 6.67% |
| FY2020 | $0.45 | — |
| FY2019 | −$0.01 | — |
| FY2018 | $0.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.18 | — |
| Mar 2026 | −$0.14 | — |
| Dec 2025 | −$0.03 | — |
| Sep 2025 | −$0.19 | — |
| 22 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| ARQT Arcutis Biotherapeutics, Inc. compare | $0.22 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ABCL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement